The 'rejuvenating factor' TIMP-2 is detectable in human blood components for transfusion.

blood components blood transfusion cognitive function morphogenesis tissue inhibitors of metalloproteinases

Journal

Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606

Informations de publication

Date de publication:
May 2021
Historique:
revised: 16 09 2020
received: 03 06 2020
accepted: 08 10 2020
pubmed: 28 10 2020
medline: 3 7 2021
entrez: 27 10 2020
Statut: ppublish

Résumé

Tissue inhibitor of metalloproteinases 2 (TIMP-2) is a protein suspected to be crucial in numerous physiological and pathological processes such as morphogenesis, tissue remodelling and metastasis suppression. In animal models, the administration of TIMP-2 to aged mice improved their cognitive functions. Therefore, one can hypothesize that differences in TIMP-2 levels between blood donors and recipients might influence cognitive functions also in humans. However, the stability of TIMP-2 during processing and storage of blood components for transfusion has not been intensively investigated so far. This study determined TIMP-2 concentrations in fresh-frozen plasma (FFP), erythrocyte concentrate (EC) and pathogen-inactivated platelet concentrate (PI-PC) depending on the donor's demographic factors age and gender. Tissue inhibitor of metalloproteinases 2 was measured in FFP (n = 30), EC (n = 12) and PI-PC (n = 12) using a Q-Plex single-plex immunoassay for chemiluminescence-based detection. Absolute quantification of TIMP-2 was performed with Q-view software. Fresh umbilical cord plasma was used as a positive control. Tissue inhibitor of metalloproteinases 2 was detected in FFP (30/30 samples), EC (11/12 samples) and PI-PC (12/12 samples). The median TIMP-2 concentration in EC (17·2 ng/ml; range: 0-26·5 ng/ml) was significantly lower compared with FFP (63·4 ng/ml; range: 44·4-87·3 ng/ml) or PI-PC (69·9 ng/ml; range: 39·9-83·6 ng/ml). Across all blood components, TIMP-2 levels are comparable in male and female donors and independent of age. Tissue inhibitor of metalloproteinases 2 is detectable and stable in FFP, PI-PC and, in low concentration, EC. It can be hypothesized that TIMP-2 will be transmitted to recipients during transfusion.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Tissue inhibitor of metalloproteinases 2 (TIMP-2) is a protein suspected to be crucial in numerous physiological and pathological processes such as morphogenesis, tissue remodelling and metastasis suppression. In animal models, the administration of TIMP-2 to aged mice improved their cognitive functions. Therefore, one can hypothesize that differences in TIMP-2 levels between blood donors and recipients might influence cognitive functions also in humans. However, the stability of TIMP-2 during processing and storage of blood components for transfusion has not been intensively investigated so far. This study determined TIMP-2 concentrations in fresh-frozen plasma (FFP), erythrocyte concentrate (EC) and pathogen-inactivated platelet concentrate (PI-PC) depending on the donor's demographic factors age and gender.
MATERIALS AND METHODS METHODS
Tissue inhibitor of metalloproteinases 2 was measured in FFP (n = 30), EC (n = 12) and PI-PC (n = 12) using a Q-Plex single-plex immunoassay for chemiluminescence-based detection. Absolute quantification of TIMP-2 was performed with Q-view software. Fresh umbilical cord plasma was used as a positive control.
RESULTS RESULTS
Tissue inhibitor of metalloproteinases 2 was detected in FFP (30/30 samples), EC (11/12 samples) and PI-PC (12/12 samples). The median TIMP-2 concentration in EC (17·2 ng/ml; range: 0-26·5 ng/ml) was significantly lower compared with FFP (63·4 ng/ml; range: 44·4-87·3 ng/ml) or PI-PC (69·9 ng/ml; range: 39·9-83·6 ng/ml). Across all blood components, TIMP-2 levels are comparable in male and female donors and independent of age.
CONCLUSION CONCLUSIONS
Tissue inhibitor of metalloproteinases 2 is detectable and stable in FFP, PI-PC and, in low concentration, EC. It can be hypothesized that TIMP-2 will be transmitted to recipients during transfusion.

Identifiants

pubmed: 33107073
doi: 10.1111/vox.13023
pmc: PMC8246888
doi:

Substances chimiques

TIMP2 protein, human 0
Tissue Inhibitor of Metalloproteinase-2 127497-59-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

533-539

Subventions

Organisme : Austrian Red Cross Dr. Karl Landsteiner Funding.
Organisme : Austrian Science Fund
ID : T 738-BBL

Informations de copyright

© 2020 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.

Références

Int J Biochem Cell Biol. 2008;40(6-7):1362-78
pubmed: 18258475
J Neurosci. 2005 May 18;25(20):4917-29
pubmed: 15901773
Prog Mol Biol Transl Sci. 2017;147:133-165
pubmed: 28413027
J Exp Med. 2009 Oct 26;206(11):2365-79
pubmed: 19808257
J Neurobiol. 2006 Jan;66(1):82-94
pubmed: 16216006
Clin Exp Pharmacol Physiol. 2008 Apr;35(4):464-9
pubmed: 18307742
Curr Opin Crit Care. 2011 Aug;17(4):376-81
pubmed: 21716111
Lab Invest. 2009 Dec;89(12):1340-7
pubmed: 19806081
Thromb Res. 2005;115(3):205-10
pubmed: 15617743
Scand J Clin Lab Invest. 2002;62(3):223-30
pubmed: 12088341
Alzheimers Dement (Amst). 2016 Jun 22;3:91-7
pubmed: 27453930
Ups J Med Sci. 2014 Aug;119(3):262-7
pubmed: 24345210
Nature. 2017 Apr 27;544(7651):488-492
pubmed: 28424512
Birth Defects Res C Embryo Today. 2006 Mar;78(1):1-10
pubmed: 16622845
PLoS One. 2009 Dec 14;4(12):e8289
pubmed: 20011518
Nature. 2011 Aug 31;477(7362):90-4
pubmed: 21886162
J Card Fail. 2007 Sep;13(7):530-40
pubmed: 17826643
Front Aging Neurosci. 2014 May 22;6:99
pubmed: 24904412
Mediators Inflamm. 2014;2014:510619
pubmed: 25114377
Front Aging Neurosci. 2017 Dec 01;9:402
pubmed: 29249965
Stem Cells Dev. 2013 Feb 1;22(3):345-58
pubmed: 23098139

Auteurs

Julia Hoefer (J)

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

Christian Dal-Pont (C)

Central Institute for Blood Transfusion & Immunological Department, University Hospital of Innsbruck, Innsbruck, Austria.

Stefan Jochberger (S)

Department of Anesthesiology and Critical Care Medicine, University Hospital of Innsbruck, Innsbruck, Austria.

Raffaella Fantin (R)

Department of Anesthesiology and Critical Care Medicine, University Hospital of Innsbruck, Innsbruck, Austria.

Harald Schennach (H)

Central Institute for Blood Transfusion & Immunological Department, University Hospital of Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH